Structure-based design and synthesis of a thyroid hormone receptor (TR) antagonist

Endocrinology

Volumn 143, Issue 2, 2002, Pages 517-524

  Baxter, John D ^a,b   Goede, Patrick ^c   Apriletti, James W ^b   West, Brian L ^b   Feng, Weijun ^b   Mellstrom, Karin ^c   Fletterick, Robert J ^a   Wagner, Richard L ^a   Kushner, Peter J ^a   Ribeiro, Ralff C J ^a   Webb, Paul ^b   Scanlan, Thomas S ^a,b   Nilsson, Stefan ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Karo Bio   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

3,5 DIBROMO 4 (3' ISOPROPYL 4' HYDROXYPHENOXY)BENZOIC ACID; 3,5 DIBROMO 4 (3',5' DIISOPROPYL 4' HYDROXYPHENOXY)BENZOIC ACID; ANTITHYROID AGENT; THYROID HORMONE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING; DRUG DESIGN; DRUG SYNTHESIS; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

EID: 18244364644     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.143.2.8617     Document Type: Article

References (70)

1. Nuclear receptor coregulators: Cellular and molecular biology
2. Introduction to endocrinology
3. Tamoxifen, raloxifene, and the prevention of breast cancer
4. Agonistic and antagonistic activities of RU486 on the functions of the human progesterone receptor
5. Mechanism of action of estrogens and selective estrogen receptor modulators
6. Novel mechanisms of progesterone antagonists and progesterone receptor
7. A retinoic acid receptor α antagonist selectively counteracts retinoic acid effects
8. Mineralocorticoid receptor antagonists: The evolution of utility and pharmacology
9. Mode of spironolactone anti-androgenic action: Inhibition of androstanolone binding to rat prostate androgen receptor
10. The thyroid: Physiology, thyrotoxicosis, hypothyroidism, and the painful thyroid
11. The effects of amiodarone on thyroid hormone function: A review of the physiology and clinical manifestations
12. Identification and measurement of desethylamiodarone in blood plasma specimens from amiodarone-treated patients
13. Antagonism of thyroid hormone action by amiodarone in rat pituitary tumor cells
14. 1-receptor protein
15. 1-receptor protein
16. 3 into the perfused rat liver
17. 1-thyroid hormone receptor
18. Amiodarone and desethylamiodarone toxicity in isolated hepatocytes in culture
19. Cytotoxic effects of amiodarone and desethylamiodarone on human thyrocytes
20. A structural role for hormone in the thyroid hormone receptor
21. Structure and specificity of nuclear receptor-coactivator interactions
22. Hormone selectivity in thyroid hormone receptors
23. Crystal structure of the ligand-binding domain of the human nuclear receptor RXRα
24. Crystal structure of the ligand binding domain of the human nuclear receptor PPARγ
25. Crystal structure of the RARγ ligand-binding domain bound to all-trans retinoic acid
26. Molecular basis of agonism and antagonism in the oestrogen receptor
27. Atomic structure of progesterone complexed with its receptor
28. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor γ
29. Nuclear-receptor ligands and ligand-binding domains
30. Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors
31. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen
32. X-ray crystallographic and functional studies of thyroid hormone receptor
33. Mechanisms of thyroid hormone action: Insights from x-ray crystallographic and functional studies
34. Synthesis and structure-activity relationships of oxamic acid and acetic acid derivatives related to L-thyronine
35. High level expression of functional full length and truncated glucocorticoid receptor in Chinese hamster ovary cells. Demonstration of ligand-induced down-regulation of expressed receptor mRNA and protein
36. Differential response of estrogen receptor α and estrogen receptor β to partial estrogen agonists/antagonists
37. High expression in mammalian cells without amplification
38. Secreted placental alkaline phosphatase: A powerful new quantitative indicator of gene expression in eukaryotic cells
39. A detailed functional and structural analysis of a major thyroid hormone inhibitory element in the human thyrotropin β-subunit gene
40. Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter
41. Plasmid-encoded hygromycin B resistance: The sequence of hygromycin B phosphotransferase gene and its expression in Escherichia coli and Saccharomyces cerevisiae
42. 1 thyroid hormone receptor ligand binding domain in Escherichia coli and the use of a ligand-induced conformation change as a method for its purification to homogeneity
43. Thyroid hormones and analogs. II. Structure-activity relationships
44. Molecular interactions between thyroid hormone analogs and the rat liver nuclear receptor. Partitioning of equilibrium binding free energy changes into substituent group interactions
45. GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors
46. Nuclear receptor coactivators
47. Direct repeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin D3 receptors
48. Thyroid hormone inhibition of human thyrotropin β-subunit gene expression is mediated by a cis-acting element located in the first exon
49. Thyroid hormone inhibits thyrotropin gene expression via a position-independent negative L-triiodothyronine-responsive element
50. Ligand-induced recruitment of a histone deacetylase in the negative-feedback regulation of the thyrotropin β gene
51. A high-affinity subtype-selective agonist ligand for the thyroid hormone receptor
52. Synthesis and biological activity of novel thyroid hormone analogues: 5′-aryl substituted GC-1 derivatives
53. A designed antagonist of the thyroid hormone receptor
54. Thyroid hormone receptor: Resistance and selective modulation
55. An antiestrogen-responsive estrogen receptor-α mutant (D351Y) shows weak AF-2 activity in the presence of tamoxifen
56. Control of the estrogen-like actions of the tamoxifen-estrogen receptor complex by the surface amino acid at position 351
57. The coregulator exchange in transcriptional functions of nuclear receptors
58. Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo
59. A new class of retinoids with selective inhibition of AP-1 inhibits proliferation
60. Similar actions of glucocorticoids and calcium on the regulation of apoptosis in S49 cells
61. Repression of interleukin-6 gene expression by 17 β-estradiol: Inhibition of the DNA-binding activity of the transcription factors NF-IL6 and NFκB by the estrogen receptor
62. Estradiol repression of tumor necrosis factor-α transcription requires estrogen receptor activation function-2 and is enhanced by coactivators
63. Mutations in the estrogen receptor ligand binding domain discriminate between hormone-dependent transactivation and transrepression
64. The transactivation domain AF-2 but not the DNA-binding domain of the estrogen receptor is required to inhibit differentiation of avian erythroid progenitors
65. 2 thyroid hormone receptor isoform in negative regulation by thyroid hormone. Mapping of a novel amino-terminal domain important for ligand-independent activation
66. 2 in the regulation of paraventricular thyrotropin-releasing hormone neurons
67. Physiological and molecular basis of thyroid hormone action
68. Sodium butyrate selectively alters thyroid hormone receptor gene expression in GH3 cells
69. 3-stimulated gene transcription